SynAct Pharma has carried out a rights issue of shares with preferential rights for existing shareholders of approximately SEK 150 million at a subscription price of SEK 63 per share.

SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The proceeds from the rights issue will be used for conducting additional clinical phase 2 development with AP1189 in rheumatoid arthritis (RA), continue development of AP1189 for kidney disease in a redesigned study setup, other research and development activities related to AP1189 and new chemical molecules and to cover general administration costs.

ABG Sundal Collier and Kempen & Co are Joint Global Coordinators in connection with the preferential rights issue. Baker McKenzie acts as legal advisor to the Joint Global Coordinators with an international Capital Markets team consisting of Joakim Falkner and Johanna Flink in Stockholm as well as Adam Farlow and Charles Farnsworth in London.

Explore Our Newsroom